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alwatohamy@yahoAbstract Two simple, accurate, precise and economic spectrophotometric methods have been
developed for simultaneous determination of Atorvastatin calcium (ATR) and Ezetimibe (EZ) in their
bulk powder and pharmaceutical dosage form. Method (I) is based on dual wavelength analysis while
method (II) is the mean centering of ratio spectra spectrophotometric (MCR) method. In method (I),
two wavelengths were selected for each drug in such a way that the difference in absorbance was zero for
the second drug. At wavelengths 226.6 and 244 nm EZ had equal absorbance values; therefore, these two
wavelengths have been used to determine ATR; on a similar basis 228.6 and 262.8 nm were selected to
determine EZ in their binary mixtures. In method II, the absorption spectra of both ATR and EZ with
different concentrations were recorded over the range 200–350, divided by the spectrum of suitable
divisor of both ATR and EZ and then the obtained ratio spectra were mean centered. The
concentrations of active components were then determined from the calibration graphs obtained by
measuring the amplitudes at 215–260 nm (peak to peak) for both ATR and EZ. Accuracy and precision
of the developed methods have been tested; in addition recovery studies have been carried out in order to
conﬁrm their accuracy. On the other hand, selectivities of the methods were tested by application for
determination of different synthetic mixtures containing different ratios of the studied drugs. The
developed methods have been successfully used for determination of ATR and EZ in their combined
dosage form and statistical comparison of the developed methods with the reported spectrophotometric
one using F and Student’s t-tests showed no signiﬁcant difference regarding both accuracy and precision.
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1. Introduction
Atorvastatin calcium (ATR) has the IUPAC name [R-(Rn,Rn)]-
2-(4-ﬂuorophenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-
4-[(phenylamino)carbonyl]-1Hpyrrole-1-heptanoic acid, calcium
salt trihydrate [1,2]. ATR belongs to a class known as statins
and it is a speciﬁc inhibitor of 3-hydroxy-3-methyl-glutaryl
coenzyme A (HMG-coA) reductase (the enzyme that cata-
lyzes the conversion of HMG-coA to mevalonate which
is the rate limiting step in the biosynthesis of cholesterol)
[3–5]. So ATR is mainly used for lowering blood
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ﬂuorophenyl)-3(R)-[(3S)-(4-ﬂuorophenyl)-3-hydroxy propyl]-
4(S) (4-hydroxyphenyl) azetidin-2-one) [7–9]. It blocks the
intestinal absorption of dietary and biliary cholesterol, with-
out affecting the uptake of triglycerides or fat soluble
vitamins. It reduces total cholesterol, LDL, and triglycerides,
and increases HDL in patients with hypercholesterolemia [10].
So it is used for the treatment of hypercholesterolemia and
homozygous sitosterolemia [11–13].
Combination of ATR and EZ has the advantages of greater
therapeutic effects than with either drug alone. This combina-
tion causes manifold reduction in LDL cholesterol level as
compared to double dose of the individual drug when used
alone [14]. Moreover, using of EZ with ATR enhances the
effects of statins at lower doses and reduces the associated side
effects [15–17].
Different methods have been reported for simultaneous
determination of ATR and EZ in their binary mixtures such as
HPLC [14], HPTLC [15], Q-spectrophotometry [16] and
derivative ratio spectrophotometric methods [17].
Due to the pharmaceutical importance of ATR and EZ
combinations, this work concerns with development and
validation of two simple, sensitive and selective spectrophoto-
metric methods for determination of the proposed drugs in
their pure forms and combined dosage form. The developed
methods do not need any derivatization steps and so signal to
noise ratio is enhanced; also they can be considered as time
and cost effective compared to the published chromatographic
methods. The developed dual wavelength analysis method is
simple and easy to be understood and applied but it can be
used only for determination of binary mixtures. On the other
hand, the developed MCR method is more selective than the
developed dual wavelength analysis and the published spectro-
photometric methods and can be used as a stability indicating
assay method [18–20].2. Experimental
2.1. Instruments
A double beam UV–visible spectrophotometer (SHIMADZU,
Japan) model UV-1601 PC with quartz cell of 1 cm and
UV-PC personal software version 3.7 was used. The spectral
band is 2 nm and scanning speed is 2800 nm/min with 0.1 nm
interval. Matlabs version 6.5 [21] was used for the proposed
mean centering of ratio spectra (MCR) spectrophotometric
method.
2.2. Materials
2.2.1. Pure standards
Standard ATR was kindly supplied by Marcyrl Pharmaceu-
tical Industries, El-Obour City, Egypt, while standard EZ was
kindly supplied by Egyptian Co. for Chemicals and Pharma-
ceuticals, ADWIA CO, 10th of Ramadan City, Egypt.
2.2.2. Pharmaceutical dosage form
Atorezas tablets (10/10)(B.N. 1031061) labeled to contain
Atorvastatin calcium equivalent to 10 mg ATR and 10 mg EZ
were manufactured by Marcyrl Pharmaceutical Industries,
El-Obour City, Egypt.2.2.3. Solvents
Methanol HPLC grade (CHROMASOLVEs, Sigma-Aldrich
Chemie GmbH, Germany) was used for the two methods.
2.2.4. Standard solutionsa. Standard stock solutions of ATR and EZ were prepared
in methanol at the concentration of 1 mg/mL.b. Standard working solutions of ATR and EZ were
prepared in methanol at the concentration of 0.1 mg/mL.2.3. Procedure
2.3.1. Spectral characteristics and wavelengths selection
The absorption spectra of 16 mg/mL each of ATR and EZ
were recorded over the range 200–350 nm using methanol as
blank. The overlaid spectra were observed for selection of the
suitable wavelengths for dual wavelength spectrophotometric
method (Fig. 1).
2.3.2. Linearity
2.3.2.1. Dual wavelength analysis method. Different aliquots
equivalent to 60–260 and 80–400 mg/mL of ATR and EZ,
were separately transferred from their respective standard
working solutions (0.1 mg/mL) into two separate series
of 10-mL volumetric ﬂasks and then the volume was com-
pleted using methanol. The prepared solutions were scanned
in the range of 200–350 nm and the absorbance values at
226.6 and 244 nm (for ATR) and at 228.6 and 262.8 nm
(for EZ) were measured. ATR was determined by plotting
the difference in absorbance values at 226.6 and 244 nm
(difference is zero for EZ) against its corresponding concen-
tration. Similarly for determination of EZ, the difference
in absorbance values at 228.6 and 262.8 nm (difference is
zero for ATR) was plotted against the corresponding
concentrations.
2.3.2.2. Mean centering of ratio spectra (MCR) method. Ali-
quots of ATR equivalent to 60–260 mg/mL were accurately
transferred from its standard working solution (0.1 mg/mL)
into a set of 10 mL measuring ﬂasks and the volume was
adjusted using methanol. The absorption spectra of the
prepared solutions were recorded in the range of 200–
290 nm, were divided by the standard spectrum of 40 mg/mL
of EZ and then the obtained ratio spectra mean centered.
By the same way the spectra of different concentrations of
standard solutions of EZ in the range of 4–40 mg/mL were
recorded. The stored spectra were divided by the standard
spectrum of 16 mg/mL of ATR to obtain the ratio spectra
which were then mean centered. Calibration curves for both
ATR and EZ were constructed by plotting the amplitude
values of their respective mean centered ratio spectra from 215
to 260 nm (peak to peak) against their corresponding
concentrations.
2.3.3. Analysis of laboratory prepared mixtures
Zero order absorption spectra of different laboratory prepared
mixtures containing different ratios of ATR and EZ were
recorded using methanol as blank and the procedure under
linearity for each method was then followed. Concentrations
Figure 1 Zero-order absorption spectra of 8 mg/mL each of ATR (—) and EZ (- - -) using methanol as a solvent.
Spectrophotometric methods for determination of antihyperlipidemic drugs 281of ATR and EZ in the prepared samples were calculated from
the computed regression equations.2.3.4. Analysis of the pharmaceutical dosage form
Fourteen tablets of Atorezas tablets were powdered and
mixed well. Accurately weighed amount of the powdered
tablets equivalent to 100 mg of ATR and EZ was transferred
to a 100-mL volumetric ﬂask and 75 mL of methanol was
added. The prepared solution was sonicated for 15 min, cooled
and the volume was completed to obtain 1 mg/mL stock
solution and then the solution was ﬁltered. Appropriate
dilutions of the prepared solution were made to prepare its
working solution (0.1 mg/mL) and the procedures under
linearity were followed.2.3.4.1. Recovery studies. To study the accuracy of the
proposed methods, recovery studies were carried out by
application of the standard addition technique. Known
amounts of the studied drugs were separately added to a
deﬁnite amount of the powdered tablet; the prepared samples
were then analyzed as under linearity and the percentage
recoveries were then calculated.3. Results and discussion
Atorvastatine and EZ act as antihyperlipedimic drugs which
have been used in the treatment of some serious diseases such
as heart diseases; hence it is very important to develop
analytical methods which are not only accurate, precise,
and rapid but also simple and economic for determination
of the studied drugs in their pharmaceutical dosage form and
this is the main task of the developed spectrophotometric
methods.
Since UV-spectrophotometric methods have the advantages
of saving time and cost when compared to the HPLC
technique, this work concerns with the development and
validation of two spectrophotometric methods, dual wave-
length and mean centering of ratio spectra spectrophotometric
methods, for determination of the suggested drugs. Moreover,
the suggested methods provide a simple, rapid, sensitive and
accurate way for simultaneous analysis of ATR and EZ in
their combined dosage without derivatization steps.3.1. Dual wavelength method
UV-absorption spectra of ATR and EZ, Fig. 1, display severe
overlap that made their direct determination in their binary
mixtures very difﬁcult. The developed dual wavelength
method provides a simple method for selective determination
of both ATR and EZ using their zero order absorption
spectra. The principle of this method is that the absorbance
difference at two points on the spectra is directly proportional
to the component of interest, independent of the interfering
component. The pre-requisite for this method is the selec-
tion of two wavelengths where the interfering component
shows the same absorbance value while the component of
interest shows signiﬁcant difference in absorbance with
concentration.
Selection of the suitable wavelengths plays an important
role; hence different wavelengths were tried such as 221.4,
258.8 and 225.4, 252.6 nm for ATR and 233.8, 260.6 and
215, 250 nm for EZ. Using the absorbance values at 226.6
and 244 nm (where EZ has the same absorbance) gave the
best selectivity when used for determination of ATR. On the
other hand absorbance values at 228.6 and 262.8 nm were
chosen for determination of EZ where the best results were
obtained. Calibration curves for ATR and EZ were con-
structed by plotting the difference in absorbance values at
the selected wavelengths for each drug against their corre-
sponding concentrations. ATR and EZ obeyed Beer Lam-
bert’s law in the concentration ranges of 6–26 and 8–40 mg/
mL for ATR and EZ, respectively with good correlation
coefﬁcients. Regression equation parameters are given in
Table 1.3.2. Mean centering of ratio spectra (MCR)
spectrophotometric method
To optimize the developed MCR method, different parameters
were tested. Since the wavelength range taken has a great
effect on the obtained mean centered ratio spectra, different
wavelength ranges were tested and the best results were obtained
when using the wavelength range from 200 to 290 nm for both
ATR and EZ. The effect of divisor concentration on the
selectivity was checked by testing several concentrations each
of EZ (normalized spectrum, 10, 20, 25 and 40 mg/mL) and ATR
(normalized spectrum, 8, 10, 12 and 16 mg/mL). The best results
Table 1 Linear regression and analytical parameters of the proposed methods for determination of ATR and EZ.
Parameters Dual wavelength method MCR method
ATR EZ ATR EZ
Linearity range (mg/mL) 6–26 8–40 6–26 4–40
Slope 0.0092 0.0202 0.0644 0.0552
Intercept 0.0097 0.009 0.0243 0.0274
Correlation coefﬁcient 0.9997 0.9999 0.9996 0.9999
Precision
Repeatability 0.924 1.071 1.754 1.033
Intermediate precision 1.273 1.145 0.945 1.156
Accuracy 100 101.66 99.68 100.4
Speciﬁcity (%) 99.897 100.877 101.817 100.457
1.594 1.292 1.199 1.067
Figure 2 Mean centered ratio spectra of ATR (6–26 mg/mL) using 40 mg/mL of EZ as a divisor and methanol as a solvent.
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16 mg/mL each of ATR and EZ, respectively as divisors.
To construct the calibration curves of the proposed method,
the absorption spectra of the standard solutions of ATR with
different concentrations were recorded in the wavelength
range of 200–290 nm and divided by the standard spectrum
of EZ (40 mg/mL). Then mean centering of the resulted ratio
spectra has been obtained and the concentrations of ATR
were determined by measuring the amplitude values of the
mean centered ratio spectra from 215 to 260 nm (peak to
peak) as shown in Fig. 2. By the same way different standard
solutions of EZ with different concentrations were recorded
and divided by the standard spectrum of ATR (16 mg/mL) and
the ratio spectra were obtained which were then mean
centered. The amplitude values from 215 to 260 nm (peak to
peak) in the obtained mean centered ratio spectra were used
for determination of EZ as shown in Fig. 3. The computedregression equation parameters for each of the studied drugs
are given in Table 1.
The speciﬁcity of the proposed methods was assessed by
analysis of different laboratory prepared mixtures containing
different ratios of the suggested drugs, where satisfactory
results were obtained and are given in Table 1. The developed
spectrophotometric methods have been also applied for
determination of ATR and EZ in Atorezas tablets and the
results obtained were acceptable with small RSD% values.
The validity of the methods was further assessed by applying
the standard addition technique which also conﬁrmed the
accuracy of the methods (Table 2). The results obtained by
applying the proposed methods for determination of Ator-
ezas tablets were statistically compared with those obtained
by applying the reported ﬁrst derivative of ratio spectra
spectrophotometric method [17] and no signiﬁcant differences
were obtained between them (Table 2).
Figure 3 Mean centered ratio spectra of EZ (4–40 mg/mL) using 16 mg/mL of ATR as a divisor and methanol as a solvent.
Table 2 Determination of the studied drugs in the laboratory prepared mixtures (L.P.), pharmaceutical preparations by the
proposed methods and statistical comparison with the reported spectrophotometric method.
Sample form Dual wavelength method MCR method Reported method [17]
ATR (%) EZ (%) ATR (%) EZ (%) ATR (%) EZ (%)
Atorezas tabletsa 99.97 101.54 100.41 102.58 99.98 102.33
(B.N.1031061) 71.80 71.06 71.05 70.97 71.05 71.12
Standard additiona 100.6 101.17 100.18 99.95
71.02 71.85 71.69 72.17
F-test (6.388)b 2.491 1.124 1.000 1.324
Student’s t-test (2.306)b 0.006 1.147 0.642 0.376
aAverage of six determination.
bThe values in the parenthesis are the corresponding theoretical values at p¼0.05.
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Validation of the method has been carried out according to
ICH recommendations [22].
3.3.1. Linearity and range
The calibration range for ATR and EZ was established
through considerations of the practical range necessary
according to adherence to Beer–Lambert’s law and the
concentrations of ATR and EZ present in the pharmaceutical
dosage form to give accurate, precise and linear results.
Linearity ranges of both ATR and EZ are shown in Table 1.
3.3.2. Accuracy
The accuracy of the results was checked by applying the
proposed methods for determination of different blind sam-
ples of ATR and EZ and the concentrations were obtainedfrom the corresponding regression equations. Good percen-
tage recoveries were obtained and are presented in Table 1.
Accuracy of the methods was further assured by applying the
standard addition technique where good percentage recoveries
were obtained, conﬁrming the accuracy of the proposed
methods (Table 2).
3.3.3. Precision
3.3.3.1. Repeatability. Three concentrations of ATR and EZ
(12, 16, 20 mg/mL) were analyzed three times intra-daily using
the proposed methods. Good percentage recoveries were
obtained, conﬁrming the repeatability of the methods (Table 1).
3.3.3.2. Intermediate precision. The previous procedures were
repeated inter-daily on three different days for the analysis of
the three chosen concentrations. The obtained percentage
recoveries were within the acceptable range (Table 1).
N.S. Abdelwahab et al.2843.3.4. Speciﬁcity
Speciﬁcity of the methods was achieved by analysis of different
laboratory prepared mixtures of ATR and EZ within their
linearity ranges. Satisfactory results are shown in Table 1.4. Conclusion
The developed dual wavelength and mean centering of ratio
spectra (MCR) spectrophotometric methods have been suc-
cessfully applied for simultaneous determination of ATR and
EZ in their combined marketed sample; they are found to be
rapid, simple, accurate and easy to be understood and applied.
On the developed dual wavelength method once the equations
were constructed, analysis required only measuring the absor-
bance values of the sample solution at the selected wavelengths
followed by a few simple calculations. On the other hand the
MCR method does not need derivatization steps or complex
algorithms. When the suggested methods were completely
validated they showed satisfactory data for all the method
validation parameters tested. Recovery studies indicated that
practically there was no interference from the tablets additives,
so these methods can be easily and conveniently adopted for
routine quality control analysis of ATR and EZ.
References
[1] A.J. Jani, A.A. Mehta, B. Dosandi, et al., Liquid chromatographic–
MS/MS determination of atorvastatin and metabolites in human
plasma,, Eurasian J. Anal. Chem. 5 (2010) 46–52.
[2] D. Liu, J. Jiang, H. Zhou, et al., Quantitative determination of
atorvastatin and para-hydroxy atorvastatin in human plasma by
LC–MS–MS, J. Chromatogr. Sci. 46 (2008) 862–866.
[3] B. Stanisz, L. Kania, Validation of HPLC method for determina-
tion of atorvastatin in tablets and for monitoring stability in solid
phase, J. Acta Pol. Pharm. 63 (2006) 471–476.
[4] A.A. Shirkhedkar, S.J. Surana, Development and validation of a
reversed-phase high-performance thin-layer chromatography–
densitometric method for determination of Atorvastatin calcium
in bulk drug and tablets, J. AOAC Int. 93 (2010) 798–803.
[5] D. Guille’n, F. Cofa’n, E. Ros, et al., Determination of atorvas-
tatin and its metabolite ortho-hydroxyatorvastatin in human
plasma by on-line anion-exchange solid-phase extraction and
liquid chromatography tandem mass spectrometry, J. Anal.
Bioanal. Chem. 394 (2009) 1687–1696.
[6] D. Skorda, C.G. Kontoyannis, Identiﬁcation and quantitative
determination of atorvastatin calcium polymorph in tablets using
FT-Raman spectroscopy, Talanta 74 (2008) 1066–1070.
[7] M. Sharma, D.V. Mhaske, M. Mahadik, et al., UV and three
derivative spectrophotometric methods for determination ofezetimibe in tablet formulation, Indian J. Pharma. Sci. 70
(2008) 258–260.
[8] E. Ucakturk, N. Ozaltin, B. Kaya., Quantitative analysis of
ezetimibe in human plasma by gas chromatography–mass spec-
trometry, J. Sep. Sci. 32 (2009) 1868–1874.
[9] R. Sistla, V.S.S.K. Tata, Y.V. Kashyap, et al., Development and
validation of a RP–HPLC method for the determination of
ezetimibe in pharmaceutical dosage forms, J. Pharm. Biomed.
Sci. 39 (2005) 517–522.
[10] S.L. Dalmora, P.R. Oliveira, T. Barth, et al., Development and
validation of a stability-indicating micellar electrokinetic chro-
matography method for the determination of ezetimibe in
pharmaceutical formulations, J. Anal. Sci. 24 (2008) 499–503.
[11] C.R. Barhate, K. Mohanraj, What is the degradation product of
ezetimibe?, J. Pharm. Biomed. Sci. 55 (2011) 1237–1238.
[12] A.K. Gajjar, V.L.D. Shah, Isolation and structure elucidation of
major alkaline degradant of Ezetimibe, J. Pharm. Biomed. Sci.
55 (2011) 225–229.
[13] S.J.S. Basha, S.A.l Naveed, N.K. Tiwari, et al., Concurrent
determination of ezetimibe and its phase-I and II metabolites
by HPLC with UV detection: quantitative application to various
in vitro metabolic stability studies and for qualitative estimation
in bile, J. Chromatogr. B. 853 (2007) 88–96.
[14] B.G. Chaudhari, N.M. Patel, P.B. Shah, et al., Stability-indicating
reversed-phase liquid chromatographic method for simultaneous
determination of atorvastatin and ezetimibe from their combina-
tion drug products, J. AOAC Int. 90 (2007) 1539–1546.
[15] B.G. Chaudhari, N.M. Patel, P.B. Shah, et al., Development and
validation of a HPTLC method for the simultaneous estimation
of atorvastatin calcium and ezetimibe, Indian J. Pharm. Sci. 68
(2006) 793–796.
[16] S.S. Sonawane, A.A. Shirkhedkar, R.A. Fursule, et al., Simulta-
neous spectrophotometric estimation of atorvastatin calcium and
ezetimibe in tablets, Indian. J. Pharm. Sci. 69 (2007) 683–684.
[17] H.M. Maher, R.M. Youssef, E.M. Hassan, et al., Enhanced
spectrophotometric determination of two antihyperlipidemic
mixtures containing ezetimibe in pharmaceutical preparations,
J. Drug Test. Anal. 3 (2011) 97–105.
[18] A. Afkhami, M. Bahram, Mean centering of ratio kinetic proﬁles
as a novel spectrophotometric method for the simultaneous
kinetic analysis of binary mixtures, Anal. Chim. Acta 526 (2)
(2004) 211–218.
[19] A. Afkhami, M. Bahram, A novel spectrophotometric method
for the simultaneous kinetic analysis of ternary mixtures by
mean centering of ratio kinetic proﬁles, Talanta 68 (4) (2006)
1148–1155.
[20] A. Afkhami, M. Bahram, Mean centering of ratio spectra as a
new spectrophotometric method for the analysis of binary and
ternary mixtures, Talanta 66 (3) (2005) 712–720.
[21] Matlab Ver. 6.5; 1999, Mathworks Inc.
[22] International Conference on Harmonization (ICH), Q2B Valida-
tion of Analytical Procedures: Methodology, vol. 62, 1997.
